Metastasis Molecular Mechanism/Biomarkers for Individual Therapy
Rui-hua Xu’s Laboratory

Prof. Rui-hua Xu’s Laboratory belongs to the Department of Medical Oncology, Sun Yat-sen University Cancer Center and State Key Laboratory of Oncology in South China. Prof. Xu’s Lab is interested in:

1) Finding novel molecular mechanisms of gastrointestinal cancer metastasis;

2) Identifying potential diagnostic and prognostic biomarkers to guide individualized therapy for cancer patients;

3) Developing new strategies to overcome drug resistance of cancer cells;

4) Conducting clinical trials for developing optimal treatments for cancer patients.

Current Research Projects
1. Role of miR-214 in the regulation of colorectal cancer liver metastasis and its underlying mechanisms.

2. Defining new molecular subtypes and developing individualized therapy for advanced colorectal and gastric cancer.

3. Role of AMPK in the regulationof Kras and PI3K signaling pathway in colorectal cancer.

4. KH903 Clinical trial: a novelanti-angiogenic antibody in the treatment of cancer patients.

Selected peer-reviewedpublications (in nearly 3 years)
1. Xu RH and Huang P*. A new rolefor PHD in chemotherapy. Cancer Cell. 22(2):143-4. (2012)

2. Satoh T, Xu RH (co-firstauthor), Chung HC, Sun GP, Doi T, Xu JM, Tsuji A, Omuro Y, Li J, Wang JW, MiwaH, Qin SK, Chung IJ, Yeh KH, Feng JF, Mukaiyama A, Kobayashi M, Ohtsu A, BangYJ: Lapatinib plus paclitaxel versus paclitaxel alone in the second-linetreatment of HER2-amplified advanced gastric cancer in Asian populations:TyTAN-a randomized, phase III study. J Clin Oncol. 32(19):2039-2049. (2014)

3. Chen DL, Wang ZQ, Zeng ZL, WuWJ, Zhang DS, Luo HY, Wang F, Qiu MZ, Wang DS, Ren C, Wang FH, Chiao LJ,Pelicano H, Huang P, Li YH, Xu RH*. Indentification of microRNA-214 as anegative regulator of colorectal cancer liver metastasis by way of regulationof fibroblast growth factor receptor 1 expression. Hepatology. 60:598-609.(2014)

4. Zeng ZL, Luo HY, Yang J, Wu WJ,Chen DL, Huang P, Xu RH*. Overexpression of the circadian clock gene Bmal1increases sensitivity to oxaliplatin in colorectal cancer. Clin Cancer Res.20(4):1042-52. (2014)

5. Qiu MZ, Li Q, Wang ZQ, Liu TS,Liu Q, Wei XL, Jin Y, Wang DS, Ren C, Bai L, Zhang DS, Wang FH, Li YH, Xu RH*.HER2-positive patients receiving trastuzumab treatment have a comparableprognosis with HER2-negative advanced gastric cancer patients: A prospectivecohort observation. Int J Cancer. 134(10):2468-77. (2014)

6. Chen DL, Wang DS, Wu WJ, ZengZL, Luo HY, Qiu MZ, Ren C, Zhang DS, Wang ZQ, Wang FH, Li YH, Kang TB, XuRH*.Overexpression of paxillin induced by miR-137 suppression promotes tumorprogression and metastasis in colorectal cancer. Carcinogenesis. 34(4):803-11.(2013)

7. Wu WJ, Zhang Y, Zeng ZL, Li XB,Hu KS, Luo HY, Yang J, Huang P, Xu RH*.β-phenylethyl isothiocyanate reversesplatinum resistance by a GSH-dependent mechanism in cancer cells withepithelial-mesenchymal transition phenotype. Biochem Pharmacol.85(4):486-96.(2013)

8. Chen DL, Zeng ZL, Yang J, RenC, Wang DS, Wu WJ, Xu RH*. L1cam promotes tumor progression and metastasis andis an independent unfavorable prognostic factor in gastric cancer. J HematolOncol. 6:43. (2013)

Contact Information
Rui-hua Xu, Ph.D.
Principle Investigator
Professor of Department of Medical Oncology
President of Sun Yat-sen University Cancer Center

651 Dong Feng East Road,
Guangzhou 510060, PR China
Office: +86-20-87343333
Fax: +86-20-87343295

Pathogenesis and etiology of NPC
Zeng Musheng's Laboratory

Prof. Musheng Zeng is a vice director and professor of Sun Yat-sen University Cancer Center. He gained his Ph.D. degree at Sun Yat-sen University in 1998 and had his Post-doc training in TennesseeState University and New England Medical Center, Tufts University from 1999 to2003. Prof. Musheng Zeng moved back to China to start his lab since 2003.

Zeng's laboratory majorly engage in the pathogenesis and etiology ofNasopharyngeal Carcinoma (NPC), especially the mechanism of EBV infection and transformation in nasopharyngeal epithelial cells. In endemic regions, NPC presents as a complex disease caused by an interaction of Epstein-Barr virus (EBV) chronic infection, environmental, and genetic factors, in a multistep carcinogenic process.

Current Research
Prof. Zeng has previously deeply studied on the genetically determined susceptibility of NPC patients and the variation of EBV, furthermore, completed the first full-length sequence analysis of an NPC-derived EBV strain.

He has already established the first cellular proto-oncogene immortalized nasopharyngeal epithelial cell line and preliminarily illuminated the mechanisms involved in the tumorigenesis of NPC, and found the functional and mechanistic links between the oncoprotein Bmi-1 and the tumor suppressor PTEN in the development and progression of cancer.

Most importantly, he recently established highly infective efficiency and stable in vitro epithelial cell model for EBV infection.
Moreover, he discovered that LMP2A induces EMT and stem-like cell self-renewal in NPC, suggesting a novel mechanism by which Epstein-Barr virus induces the initiation, metastasis and recurrence of NPC.

Contact Information
Zeng Mu-Sheng
Principle Investigator
Professor of Experimental Research
Sun Yat-sen University

651 Dong Feng Road, East Guangzhou, China 510060
Phone: 020-87343191

Cellular and molecular mechanism of cancer metastasis
Chao-Nan Qian's Laboratory

The laboratory of Chao-Nan Qian, M.D., within the State Key Laboratory of Oncology in South China, SYSUCC.  Qian's Lab is interested in understanding the cellular and molecular mechanism of cancer metastasis, tumor angiogenesis, and carcinogenesis, with multidisciplinary approaches and tools including in vitro molecular and biological assays, as well as in vivo animal models.

Current Research
1.       Molecular mechanisms underlying metastasis of nasopharyngeal carcinoma.

2.       Molecular mechanisms underlying angiogenesis of solid tumors.

3.       Molecular mechanisms underlying cancer onset in different ages.

Contact Information
Chao-Nan Qian, M.D., Ph.D.
Principle Investigator
Professor and Vice President
Sun Yat-sen University Cancer Center

651 Dongfeng East Road
Guangzhou, Guangdong 510060
Office: +86-20-87343457; +86-20-87343606
Fax: +86-20-87343624

Genetic mechanisms and/or prediction biomarkers of cancer metastasis
Dan Xie's Laboratory

The laboratory of Dan Xie, M.D., Ph.D. is within the Sun Yat-Sen University Cancer Center for basic and translational  studies on cancer metastasis and anticancer drugs research. The Xie Lab is interested in understanding the genetic mechanisms and/or prediction biomarkers of cancer metastasis in several types of human cancers including colorectal,  hepatoceullar, esophageal, lung and ovarian carcinomas.

Current Research
1.      The molecular carcinogenic characteristics and clinical significance of new candidate oncogene EIF5A2 in colorectal cancer metastasis.

2.      The role of the Polycomb EZH2 in hepatocellular carcinoma metastasis and the screening and molecular mechanism of its silence of tumor suppressor.

3.      Studies on the molecular functions and mechanism of miRNA-148 in the malignant progress of primary hepatocellular carcinoma.

Contact Information
Dan Xie, M.D., Ph.D.
Principle Investigator
The State Key Laboratory of Oncology in Southern China
Deputy Head
The Department of Pathology
Sun Yat-Sen University Cancer Center

Lab729, Building 2
No. 651, Dongfeng Road East
Guangzhou, 510060
Office: (8620) 87343193
Fax: (8620) 87343170

Clinical Research of new anti-tumor drugs
Jiang Wenqi's Laboratory

The laboratory of Professor Wenqi Jiang is within the State Key Laboratory of Oncology in South China of Sun Yat-sen University Cancer Center. The Jiang Lab is focus on the clinical research of new anti-tumor drugs, the mechanism of molecule-targeting agents, and the clinical apply of biotherapy in lymphoma and other cancer.

Contact Information
Wenqi Jiang, M.D., Professor
Principle Investigator

651 Dongfeng Road East
Office: +86 20 87343352

Molecular phenotypes and staging of ovarian carcinoma
Liu Jihong's Laboratory

The laboratory of Jihong Liu, Professor, is within the Sun Yat-sen university cancer center. Liu's Lab is interested in the study of molecular phenotypes and staging of ovarian carcinoma, biomarkers for early diagnosis of ovarian cancer, as well as lymph node metastasis in cervical cancer. The ability to predict responses to chemotherapy is another key point of our research projects in ovarian cancer.

Current Research
1.Study of clinical classifications and molecular phenotypes in ovarian cancer

  Molecular features of different metastasis patterns in stage III ovarian cancer

  Establishment of an animal model for retroperitoneal lymph node metastasis

  Screening molecules related to lymph node metastasis in ovarian cancer

2.Study of molecular biology on lymph node metastasis in cervical cancer

  u  Biological functions of Sam68 and underlying molecular mechanisms relation to lymph node metastasis

  u  Relationship between Sam68 and angiogenesis

  u  Expression and clinical significance of URG4 in cervical cancer

Contact Information
Professor Jihong Liu
Department of Gynecologic Oncology
Sun Yat-sen University Cancer Center

651 Dongfeng Road East
Office:+86 20 87343102
Fax:+86 20 87343014

Prognosis prediction and comprehensive treatment of NPC
Ma Jun's Laboratory

The laboratory of Jun Ma, M.D. is interested in prognosis prediction and comprehensive treatment of nasopharyngeal carcinoma. He has done a solid job in improving the TNM staging system, identifying different prognostic factors, and investigating novel therapeutic strategies for nasopharyngeal carcinoma (NPC). Jun lab has published over 49 papers in prestigious, international peer-reviewed journals, such as Lancet Oncol, J Clin Oncol, Clin Cancer Res, Cancer, Radiology, Radiother Oncol, and Int J Radiat Oncol Biol Phys.

Current research
1. Establish novel TNM-biomarker-based prognostic classifiers.

2. Develop an individualized target volume delineation system for intensity modulated radiotherapy.

3. Identify effective drug therapy for the eradication of micrometastases. 

Contact Information
Jun Ma, M.D.
Principle Investigator
Department of Radiation Oncology
Sun Yat-sen University Cancer Center
State Key Laboratory of Oncology in South China

651 Dongfeng Road East,
Guangzhou 510060,
People's Republic of China
Office:(+86) 020-87343469
Fax:(+86) 020-87343392

Brain cancer genetic resistanceBrain cancer genetic resistance/drug resistance in glioma/vasculogenic mimicry (VM) in glioma
Chen Zhong-ping's Laboratory

The laboratory of Neurosurgery/Neuro-oncology is one of the labs in Department of Experimental Research of Sun Yat-sen University Cancer Center (SYSUCC). The head of the lab is Dr. Zhong-ping Chen, who is also the chairman of Department of Neurosurgery/Neuro-oncology of SYSUCC. The lab’s directions are the following:
1) Genetic alterations leading to resistance of human brain tumors to chemotherapy, and has found that ERCC2, one of the important components in nucleotide excision repair (NER) system related to alkylating agent resistance in human tumor cell lines;

2) MGMT associated drug resistance in glioma has also been investigated and applied in his clinical practice;

3) Vasculogenic mimicry (VM) in glioma were first reported by us, which is anew circulation pattern exists in malignant gliomas.

As a successful surgeon, Dr. Chen also interests in microsurgery and multimodality treatment for primary and metastatic tumors in central nervous system, particularly gliomas. Dr Chen has been awarded Francis Mc Naughton Memorial Prize in 1998 (Canadian Neurological Society), WHO Prize for Chinese Young Professional in Mental Health & Neuroscience in 1993,and Wang Chong-cheng Academic Award for Chinese Neurosurgeon in 2006. More than200 papers have been published in leading scientific journals by our lab members,  including Cancer Research, Clinical Cancer Research, Journal of National Cancer Institute, Neurosurgery, Journal of Neurosurgery, Journal of Neuro-oncology, and Neuro-oncology.

Current Research
1. Study of molecular mechanisms of VEGF regulating the transition from vasculogenic mimicry to tumor-derived vessels in glioma

2. The study of molecular typing and biomarker in gioma in Chinese population

3. The anticancer effect of combination therapy with temozolomide and levetiracetam inglioma

4. The mechanism of the DLL4-Notch1 regulated vasculogenic mimicry transition inglioma

5. The prognostic biomarkers study in glioblastoma multiforme

6. The role of delta-PI3K in the metastasis process of glioblastoma multiforme

Contact Information
Zhong-ping Chen, M.D., Ph.D.
Professor & Chairman
Department of Neurosurgery/Neuro-oncology
Sun Yat-sen University Cancer Center

Sun Yat-sen University Cancer Center, Building 2, Room 926
651 Dongfeng Road East, Guangzhou,Guangdong, China, 510060
Tel & Fax: 86-20-87343169



Molecular and cellular mechanisms of cancer
Liu Quentin's Laboratory

The Quentin Liu's lab is interested in understanding the molecular and cellular mechanisms of cancer through mammalian cell culture, animal models and clinical resources. We seek to identify diagnostic markers and therapeutic targets for cancer of various tissues. A unique three-dimensional culture system has been developed in our group to better interpret the in vivo microenvironment of cancer. We are currently investigating cancer stem cell biology and the differentiation of solid tumors, identifying the molecular mechanisms involved and the translational applications.

Current Research

1. Epigenetics, cancer stem cell biology and differentiation of cancer.

2. Molecular markers and targeted drugs for cancer.

3. Three-dimensional culture of normal/malignant cells.

Contact Information

Quentin Liu, MD, PhD

Principle Investigator

Professor of Cancer Biology

Director, Laboratory for Target Therapy,State Key Laboratory of Oncology, Cancer Center

Sun Yat-senUniversity (SYSU)


651 Dongfeng Road East

Guangzhou, Guangdong 510060

Tel: 020-87343148


Screening and validating tumor radiobiological markers and clinical prognostic indicators
Xia Yunfei's Laboratory

The laboratory of Prof. Yunfei Xia, is within the Sun Yat-sen University Cancer Center. The team of Prof. Xia is mainly engaged in screening and validating tumor radiobiological markers and clinical prognostic indicators.In basic research, Xia lab established spectroscopic techniques and parameters to detect the radio sensitivity of nasopharyngeal carcinoma based on free radicals, light biology, molecular biology and proteomics; revealed mechanisms of NPC radio-resistance such as p53-p21, DNA-PK / ATM-DNA repair pathways, cell cycle and apoptosis; screened predictive and prognostic indicators for nasopharyngeal carcinoma diagnosis by MALDI-TOF MS-based technologies. From Clinical scale, Xia lab divided NPC into four radiotherapy-related types as follows, Type I: radiosensitive and non-metastasis-prone, Type II: radioresistant and non-metastasis-prone, Type III: radiosensitive and metastasis-prone, and Type IV: radioresistant and metastasis-prone; found prognosis indicators of NPC from routine blood and biochemical  examinations and therefore established the prognosis model. Moreover, Xia lab proposed improved glioma postoperative radiation therapy biological target.

Current Research
1. Tumor radiobiological behavior related clinical and molecular typing research .

2. Study of nasopharyngeal carcinoma individualized treatment based on badiobiological behavior.

Contact Information
Yunfei Xia, prof.
Chief physician
Deputy director
Radiation Oncology Department of Sun Yat-sen university cancer center
Address: No. 651, Room 926 , Building 2, Sun Yat-sen university Cancer Center,Dongfeng East Road, Yuexiu District, Guangzhou.
Office: 020-87343169

Mechanisms involved in hepatocarcinogenesis and tumor metastasis
Yun Jing Pings' Laboratory

Dr. Yun is a certified anatomic pathologist, specialized in tumor pathology. He obtained his medical degree at Sun Yat-sen University and completed his PhD training at the Chinese University of Hong Kong. He then returned to Guangzhou to start his own laboratory at Sun Yat-sen University Cancer Center. Dr. Yun is the Chair and Professor of department of Pathology.

Current Research
The Yun’s research team engages in basic and translational researches of the mechanisms involved in hepatocarcinogenesis and tumor metastasis. Particular interests are given to identify the biomarkers that are of critical importance in cancer diagnosis and prognostic prediction, and to investigate the related aberrant signaling pathways. We have discovered many novel protein alterations in hepatocellular carcinoma, and these discoveries have advanced our understanding of how the involved proteins transmit signals that cause cancer cells to become invasive and metastatic. Our research has won several accolades, with prestigious grants and significant publications.


Contact Information
Yun Jing Ping
Chair and Professor
Department of Pathology
651 Dongfeng East Road
Guangzhou 510060,China

Transcriptional regulation of inflammation and cancer-related genes
Deng Wuguo's Laboratory

The Deng Laboratory, under the supervision of Dr. Wuguo Deng, studies the transcriptional regulation of inflammation and cancer-related genes and the molecular mechanisms of these genes in regulating tumor development and progression using multidisciplinary approaches and tools including streptavidin bead-based DNA binding protein pull down system, mass spectrometry-based proteomics, siRNA library screening, protein expression and structural analyses, tissue micro array, mammalian cell culture and animal models. The Deng Laboratory is part of the State Key Laboratory of Oncology in South China and the Department of Experimental Research at Sun Yat-sen University Cancer Center.

Current Research
1. Transcriptional regulation of inflammation and cancer-related genes such as COX-2, iNOS,p300/CBP, hTERT.

2. Discovery and identification of the novel cancer biomarkers and therapeutic targets and the mechanisms of actions of candidate genes in regulating tumor cell growth.

Contact Information
Wuguo Deng, Ph.D.
Principle Investigator
Department of Experimental Research
Sun Yat-sen University Cancer Center

651 Dongfeng East Road
Building 2, Room 705
Guangzhou 510060,China


1.       Yu Z, Guo W, Ma X, Zhang B, Dong P,Huang L, Wang X, Wang C, Huo X, Yu W, Yi C, Xiao Y, Yang W, Qin Y, Yuan Y, MengS, Liu Q, Deng W*. Gamabufotalin,a bufadienolide compound from toad venom, suppresses COX-2 expression throughtargeting IKKbeta/NF-kappaB signaling pathway in lung cancer cells. Mol Cancer. 2014 Aug 31;13(1):203. [Epub ahead of print]

2.       Guo W, Lu J, Dai M, Wu T, Yu Z, Wang J,Chen W, Shi D, Xiao Y, Yi C, Tang Z, Yu T, Xiao X, Yuan Y, Kang T, Huang W, Deng W*. Transcriptionalcoactivator CBP upregulates hTERT expression and tumor growth and predicts poorprognosis in human lung cancers. Oncotarget. 2014 Aug 30; [In Press]

3.       Chen W, Wang J, Qin Y, Yu W, Guo W, TuanY, Sji D, Fu L, Kang TB, Huang W, DengW*. Ret finger protein-like 3 promotes tumor cell growth by activating telomerase reversetranscriptase expression in non–smallcell lung cancer cells. Oncotarget. 2014 Sep 7; [InPress]

4.       Liang X, Shi D, Yun J, Mao Y, Ouyang P,Su Z, Fu J, Hou J, Deng W*, Xie F. Friendleukemia virus integration 1 expression has prognostic significance innasopharyngeal carcinoma. Transl Oncol. 2014 Aug;7(4):493-502.

5.       Jiang K, Li Y, Zhu Q, Xu J, Wang Y, Deng W, Liu Q, Zhang G, Meng S. Pharmacologicalmodulation of autophagy enhances Newcastle disease virus-mediated oncolysis indrug-resistant lung cancer cells. BMC Cancer. 2014 Jul 30;14:551.

6.       Yi C, Zhang Y, Yu Z, Xiao Y, Wang J, QiuH, Yu W, Tang R, Yuan Y, Guo W, Deng W*. Melatoninenhances the anti-tumor effect of fisetin by inhibiting COX-2/iNOS andNF-κB/p300 signaling pathways. PLoS One. 2014 Jul 7;9(7):e99943.

7.       Hu K, Liao D, Wu W, Han AJ, Shi HJ, WangF, Wang X, Zhong L, Duan T, Wu Y, Cao J, Tang J, Sang Y, Wang L, Lv X, Xu S,Zhang RH, Deng WG, Li SP, Zeng YX,Kang T. Targeting theanaphase-promoting complex/cyclosome (APC/C)- bromodomain containing 7 (BRD7)pathway for human osteosarcoma. Oncotarget. 2014 May 30;5(10):3088-100.

8.       Lin L, Deng W*, Tian Y, Chen W, Wang J, Fu L, Shi D, Zhao M, Luo W. Lasiodininhibits proliferation of human nasopharyngeal carcinoma cells by simultaneousmodulation of the Apaf-1/caspase, AKT/MAPK and COX-2/NF-κB signaling pathways. PLoS One. 2014 May 20;9(5):e97799.

9.       Fu L, Shi K, Wang J, Chen W, Shi D, TianY, Guo W, Yu W, Xiao X, Kang T, Wang S, Huang W, Deng W*. TFAP2B overexpressioncontributes to tumor growth and a poor prognosis of human lung adenocarcinomathrough modulation of ERK and VEGF/PEDF signaling. Mol Cancer. 2014 Apr 26;13:89.

10.   Ye W, Liu R, Pan C, Jiang W, Zhang L,Guan Z, Wu J, Ying X, Li L, Li S, Tan W, Zeng M, Kang T, Liu Q, Thomas GR,Huang M, Deng W, Huang W. Multicenterrandomized phase 2 clinical trial of a recombinant human endostatin adenovirusin patients with advanced head and neck carcinoma. Mol Ther. 2014 Jun;22(6):1221-9.

11.   Chen W, Qin L, Wang S, Li M, Shi D, TianY, Wang J, Fu L, Li Z, Guo W, Yu W, Yuan Y, Kang T, Huang W, Deng W*. CPSF4 activates telomerasereverse transcriptase and predicts poor prognosis in human lungadenocarcinomas. Mol Oncol. 2014May;8(3):704-16.

12.   Shi D, Xie F, Zhang Y, Tian Y, Chen W,Fu L, Wang J, Guo W, Kang T, Huang W, DengW*. TFAP2A regulatesnasopharyngeal carcinoma growth and survival by targeting HIF-1α signalingpathway. Cancer Prev Res (Phila). 2014 Feb;7(2):266-77.

13.   Chen W, Guo W, Li M, Shi D, Tian Y, LiZ, Wang J, Fu L, Xiao X, Liu QQ, Wang S, Huang W, Deng W*. Upregulation of cleavageand polyadenylation specific factor 4 in lung adenocarcinoma and its criticalrole for cancer cell survival and proliferation. PLoS One. 2013 Dec 16;8(12):e82728.

14.   Ouyang PY, Su Z, Mao YP, Liang XX, LiuQ, Deng W*, Xie FY. Prognosticimpact of cigarette smoking on the survival of patients with establishednasopharyngeal carcinoma. CancerEpidemiol Biomarkers Prev. 2013 Dec;22(12):2285-94.

15.   Ouyang PY, Su Z, Mao YP, Deng W*, Xie FY. Combinationof EGFR-TKIs and chemotherapy as first-line therapy for advanced NSCLC: ameta-analysis. PLoS One. 2013Nov 13;8(11):e79000.

16.   Fu L, Chen W, Guo W, Wang J, Tian Y, ShiD, Zhang X, Qiu H, Xiao X, Kang T, Huang W, Wang S, Deng W*. Berberine TargetsAP-2/hTERT, NF-κB/COX-2, HIF-1α/VEGF and Cytochrome-c/Caspase Signaling toSuppress Human Cancer Cell Growth. PLoS One. 2013 Jul 15;8(7):e69240.

17.    Wang L, Yuan C, Lv K, Xie S, Fu P, Liu X, Chen Y, Qin C, Deng W*, Hu W. Lin28mediates radiation resistance of breast cancer cells via regulation of caspase,H2A.X and Let-7 signaling. PLoS One.2013 Jun 20;8(6):e67373.

18.    Wang J, Liu L, Qiu H, Zhang X, Guo W, Chen W, Tian Y, FuL, Shi D, Cheng J, Huang W, Deng W*.Ursolic acid simultaneously targets multiple signaling pathwaysto suppress proliferation and induce apoptosis in colon cancer cells. PLoS One. 2013 May 30;8(5):e63872.

19.    Wang J, Guo W, Chen W, Yu W, Tian Y, Fu L, Shi D, Tong B,Xiao X, Huang W, Deng W*. Melatoninpotentiates the antiproliferative and pro-apoptotic effects of ursolic acid incolon cancer cells by modulating multiple signaling pathways. J Pineal Res. 2013 May;54(4):406-16.

20.   Guo W, Chen W, Yu W, Huang W, Deng W*. Small interferingRNA-based molecular therapy of cancers. Chin J Cancer.2013 Sep;32(9):488-93.

21.    Qin Y, Deng W,Ekmekcioglu S, Grimm EA. Identification of unique sensitizing targets foranti-inflammatory CDDO-Me in metastatic melanoma by a large-scale syntheticlethal RNAi screening. Pigment Cell MelanomaRes. 2013 Jan;26(1):97-112.

22.   Shi D, Guo W, Chen W, Fu L, Wang J, TianY, Xiao X, Kang T, Huang W, Deng W*. Nicotinepromotes proliferation of human nasopharyngeal carcinoma cells by regulatingα7AChR, ERK, HIF-1α and VEGF/PEDF signaling. PLoS One. 2012;7(8):e43898.

23.   Lv K, Liu L, Wang L, Yu J, Liu X, ChengY, Dong M, Teng R, Wu L, Fu P, Deng W*,Hu W, Teng L. Lin28 mediates paclitaxelresistance by modulating p21, Rb and Let-7a miRNA in breast cancer cells. PLoS One. 2012;7(7):e40008.

24.   Shi D, Xiao X, Wang J, Liu L, Chen W, FuL, Xie F, Huang W, Deng W*. Melatoninsuppresses proinflammatory mediators in lipopolysaccharide-stimulated CRL1999cells via targeting MAPK, NF-κB, c/EBPβ, and p300 signaling. J Pineal Res. 2012 Sep;53(2):154-65.

25.   Wang J, Xiao X, Zhang Y, Shi D, Chen W,Fu L, Liu L, Xie F, Kang T, Huang W, DengW*. Simultaneous modulation ofCOX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferationand induce apoptosis in breast cancer cells. J Pineal Res. 2012 Aug;53(1):77-90.

26.   Tang QL, Xie XB, Wang J, Chen Q, Han AJ,Zou CY, Yin JQ, Liu DW, Liang Y, Zhao ZQ, Yong BC, Zhang RH, Feng QS, Deng WG, Zhu XF, Zhou BP, Zeng YX, ShenJN, Kang T. Glycogen synthasekinase-3β, NF-κB signaling, and tumorigenesis of human osteosarcoma. J Natl Cancer Inst. 2012 May 16;104(10):749-63.

27.    DengWG,Kwon J, Ekmekcioglu S, Poindexter NJ, Grimm EA. IL-24 gene transfersensitizes melanoma cells to erlotinib through modulation of the Apaf-1 and Aktsignaling pathways. Melanoma Res. 2011 Feb;21(1):44-56.

28.   Xiao X, Shi D, LiuL, Wang J, Xie X, Kang T, Deng W*. Quercetinsuppresses cyclooxygenase-2 expression and angiogenesis through inactivation ofP300 signaling. PLoS One.2011;6(8):e22934.

29.    DengWG,Wu G, Ueda K, Xu K, Roth JA, Ji L. Enhancementof antitumor activity of cisplatin in human lung cancer cells by tumorsuppressor FUS1. Cancer Gene Ther.2008 Jan;15(1):29-39.

30.    DengWG,Jayachandran G, Wu G, Xu K, Roth JA, Ji L. Tumor-specific activationof human telomerase reverses transcriptase promoter activity by activatingenhancer-binding protein-2beta in human lung cancer cells. J Biol Chem. 2007 Sep 7;282(36):26460-70.

31.    DengWG,Montero AJ, Wu KK. Interferon-gammasuppresses cyclooxygenase-2 promoter activity by inhibiting C-Jun and C/EBPbetabinding. Arterioscler Thromb Vasc Biol. 2007 Aug;27(8):1752-9.

32.   Lin J, Sun T, Ji L, Deng W, Roth J, Minna J, Arlinghaus R. Oncogenicactivation of c-Abl in non-small cell lung cancer cells lacking FUS1expression: inhibition of c-Abl by the tumor suppressor gene product Fus1. Oncogene. 2007 Oct 25;26(49):6989-96.

33.   Ohtani S, Iwamaru A, Deng W, Ueda K, Wu G, Jayachandran G,Kondo S, Atkinson EN, Minna JD, Roth JA, Ji L. Tumor suppressor 101F6 andascorbate synergistically and selectively inhibit non-small cell lung cancergrowth by caspase-independent apoptosis and autophagy. Cancer Res. 2007 Jul 1;67(13):6293-303.

34.    DengWG,Nishizaki M, Fang B, Roth JA, Ji L. Inductionof apoptosis by tumor suppressor FHIT via death receptor signaling pathway inhuman lung cancer cells. Biochem BiophysRes Commun. 2007 Apr 20;355(4):993-9.

35.    DengWG, Kawashima H, Wu G, Jayachandran G, Xu K, Minna JD, Roth JA, Ji L. Synergistictumor suppression by coexpression of FUS1 and p53 is associated withdown-regulation of murine double minute-2 and activation of the apoptoticprotease-activating factor 1-dependent apoptotic pathway in human non-smallcell lung cancer cells. Cancer Res. 2007 Jan 15;67(2):709-17.

36.   Ueda K, Kawashima H, Ohtani S, Deng WG, Ravoori M, Bankson J, Gao B,Girard L, Minna JD, Roth JA, Kundra V, Ji L. The 3p21.3 tumorsuppressor NPRL2 plays an important role in cisplatin-induced resistance inhuman non-small-cell lung cancer cells. Cancer Res.2006 Oct 1;66(19):9682-90.

37.   Cieslik KA, Deng WG, Wu KK. Essentialrole of C-Rel in nitric-oxide synthase-2 transcriptional activation:time-dependent control by salicylate. Mol Pharmacol.2006 Dec;70(6):2004-14.

38.    DengWG,Tang ST, Tseng HP, Wu KK. Melatonin suppressesmacrophage cyclooxygenase-2 and inducible nitric oxide synthase expression byinhibiting p52 acetylation and binding. Blood.2006 Jul 15;108(2):518-24.

39.    Deng WG, Zhu Y, Wu KK. Roleof p300 and PCAF in regulating cyclooxygenase-2 promoter activation byinflammatory mediators. Blood.2004 Mar 15;103(6):2135-42.

40.    DengWG, Zhu Y, Montero A, Wu KK. Quantitative analysis ofbinding of transcription factor complex to biotinylated DNA probe by astreptavidin-agarose pulldown assay. Anal Biochem.2003 Dec 1;323(1):12-8.

41.    DengWG,Wu KK. Regulation of induciblenitric oxide synthase expression by p300 and p50 acetylation. J Immunol. 2003 Dec 15;171(12):6581-8.

42.    Deng WG, Zhu Y, Wu KK. Up-regulationof p300 binding and p50 acetylation in tumor necrosis factor-alpha-inducedcyclooxygenase-2 promoter activation. J Biol Chem.2003 Feb 14;278(7):4770-7.

43.    DengWG,Saunders M, Gilroy D, He XZ, Yeh H, Zhu Y, Shtivelband MI, Ruan KH, Wu KK. Purificationand characterization of a cyclooxygenase-2 and angiogenesis suppressing factorproduced by human fibroblasts. FASEB J. 2002 Aug;16(10):1286-8.

44.   Schroer K, Zhu Y, Saunders MA, Deng WG, Xu XM, Meyer-Kirchrath J, WuKK. Obligatory role of cyclicadenosine monophosphate response element in cyclooxygenase-2 promoter inductionand feedback regulation by inflammatory mediators. Circulation.2002 Jun 11;105(23):2760-5.

45.   Zhu Y, Saunders MA,Yeh H, Deng WG, Wu KK. Dynamicregulation of cyclooxygenase-2 promoter activity by isoforms ofCCAAT/enhancer-binding proteins. J BiolChem. 2002 Mar 1;277(9):6923-8.

46.    Deng WG, Ruan KH, Du M,Saunders MA, Wu KK. Aspirinand salicylate bind to immunoglobulin heavy chain binding protein (BiP) andinhibit its ATPase activity in human fibroblasts. FASEB J. 2001 Nov;15(13):2463-70.

47.   Liou JY, Deng WG, Gilroy DW, Shyue SK, Wu KK. Colocalization andinteraction of cyclooxygenase-2 with caveolin-1 in human fibroblasts. J Biol Chem. 2001 Sep 14;276(37):34975-82.

48.    Deng W, HeY, Fang X, Wu J. Radiolysisof rutin in aerated ethanolic solution.Radiat Phys Chem. 1998; 53:629-33.

49.    Deng W, Fang X, Wu J. Flavonoidsfunction as antioxidants: By scavenging reactive oxygen species or by chelatingiron? Radiat Phys Chem. 1997; 50:273-5.

50.   Yi QM, Deng WG, Xia ZP, Pang HH. Polymorphismand genetic relatedness among wild and cultivated rice species determined byAP-PCR analysis. Hereditas.1995;122(2):13ww5-41.

Characterization of cancer-related genes
Xin-Yuan Guan's Laboratory

The laboratory of Xin-Yuan Guan, Ph.D. is within the State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center. The research interests of Guan Lab include the characterization of cancer-related genes, cancer stem cells and tumor microenvironment in hepatocellular carcinoma (HCC) and esophageal squamous cell carcinoma (ESCC) with multidisciplinary approaches and tools such as FISH, in vitro and in vivo functional assays, deep sequencing analysis, stemness-associated assays, and metastatic animal models. 

Current Research
1.  Identification and characterization of cancer-related genes in HCC and ESCC.

2.  Characterization of FGFR2+ cancer-associated fibroblasts(CAFs) in ESCC.

3.  Identification and characterization of cancer stem cells (CSCs) in HCC and


4.  Investigation of the role of HBV X gene in HCC pathogenesis.

Contact Information
Xin-Yuan Guan, Ph.D.
Principle Investigator,
State Key Laboratory of Oncology in South China
Collaborative Innovation Center for Cancer Medicine
Sun Yat-Sen University Cancer Center

Room 706, West Building,
No.651 Dongfeng Road East,
Guangzhou 510060, China.
Office: 86-20-87343166

Gene function and regulation
Xia Jian-Chuan's Laboratory

The laboratory of Jian-Chuan Xia, Ph.D. is within the State Key Laboratory of Oncology in South China. Xia's Lab is interested in gene function and regulation related to cancer and cancer immunotherapy study, with multidisciplinary approaches and tools including immuno histochemistery, Enzyme-linked immunosorbent assay (ELISA), Real-time quantitative RT-PCR, western blotting, flow cytometry , immune cell culture and electroporation  and establish rat models of cancer.

Current Research
(1) Cancer genetics study
Tumor suppressor gene down-regulation may play an important role in tumor progress and development. We investigated several tumor suppressors such as ING2,TESTIN, BATF2, LZAP and BIN1, et al. expression in primary hepatocellular carcinoma(HCC) or gastric cancer (GC) and evaluated the relationship between these tumor suppressors’ expression and clinico pathological parameters of HCC or GC.  Meanwhile, the prognostic value of these tumor suppressors for HCC or GC patients was also investigated.  Furthermore, by examining in vitro proliferation, clone formation, motility, invasion and apoptosis of tumor cell lines, he also study the functional role of these tumor suppressors in the tumorigenesis of HCC or GC.
(2)Cancer Immunotherapy study
Immunotherapy is an important comprehensive treatment method for cancer patient. In Dr. Xia’s group, he investigated several immuno-effector cells such as cytokines induced killer cells (CIK), natural killer cells (NK), dendritic cells (DC) and DC-CIK for treatment of cancer patients. Furthermore, he investigated negative regulator such as SOCS1 and IDO for the function of DC, and studied whether silencing these negative regulators could enhance the anti-tumor immunity of DC. Moreover, he also investigated that DC/tumor fusion vaccines or genetic modified-DC vaccines for the treatment of cancer patients.
Contact Information
Jian-Chuan Xia, Ph.D.
Principle Investigator
Department of Cell therapy and Healthcare Research Center

Rm#832, 651 Dongfeng Road East Guangzhou, Guangdong 510060, P.R. China
Office: (020)87343404


1. Zhao JJ, Pan QZ, Pan K, Weng DS, Wang QJ, Li JJ, Lv L, Wang DD, Zheng HX, Jiang SS, Zhang XF, Xia JC(Corresponding). Interleukin-37 Mediates the Antitumor Activity in Hepatocellular Carcinoma: Role for CD57+ NK Cells. Sci Rep. 2014 Jun 5;4:5177.

2. Pan K, Guan XX, Li YQ, Zhao JJ, Li JJ, Qiu HJ, Weng DS, Wang QJ, Liu Q, Huang LX, He J, Chen SP, Ke ML, Zeng YX, Xia JC(Corresponding). Clinical activity of adjuvant cytokine-induced killer cell (CIK) immunotherapy in patients with post-mastectomy triple-negative breast cancer patients. Clin Cancer Res. 2014 Jun 1;20(11):3003-11.

3. Keshari RP, Wang W, Zhang Y, Wang DD, Li YF, Yuan SQ, Qiu HB, Huang CY, Chen YM, Xia JC (Corresponding), Zhou ZW. Decreased Expression of the GATA3 Gene Is Associated with Poor Prognosis in Primary Gastric Adenocarcinoma. PLoS One. 2014 Feb 4;9(2):e87195

4.       YangXB, Zhao JJ, Huang CY, Wang QJ, Pan K, Wang DD, Pan QZ, Jiang SS, Lv L, Gao X,Chen HW, Yao JQ, Zhi M, Xia JC (Corresponding). Decreased Expression of theFOXO3aGene Is Associated withPoor Prognosis in Primary Gastric Adenocarcinoma Patients. PLoS One. 2013 Oct 230;8(10): e78158

5.       Pan QZ, Pan K, Zhao JJ, Chen JG, Li JJ, Lv L, WangDD, Zheng HX, Jiang SS, Zhang XF, Xia JC (Corresponding). Decreased expressionof interleukin-36α correlates with poor prognosis in hepatocellular carcinoma. Cancer ImmunolImmunother. 2013 Sep 6.

6.       Lu L, Pan K, Zheng HX, Li JJ, Qiu HJ, Zhao JJ, WengDS, Pan QZ, Wang DD, Jiang SS, Chang AE, Li Q, Xia JC (Corresponding). IL-17Apromotes immune cell recruitment inhuman esophageal cancers and the infiltrating dendritic cells represent apositive prognostic marker for patient survival. J Immunother. 2013 Oct;36(8):451-8.

7.       Pan K, Wang QJ, Liu Q, Zheng HX, Li YQ, Weng DS, LiJJ, Huang LX, He J, Chen SP, Ke ML, Zeng YX, Xia JC (Corresponding). Thephenotype of ex vivo generated cytokine-induced killer cells is associated withoverall survival in patients with cancer. TumourBiol. 2013 Aug 17.

8.       Huang CY, Zhao JJ, Lv L, Chen YB, Li YF, Jiang SS,Wang W, Pan K, Zheng Y, Zhao BW, Wang DD, Chen YM, Yang L, Zhou ZW, Xia JC(Corresponding). Decreased Expression of AZGP1 Is Associated with PoorPrognosis in Primary Gastric Cancer. PLoSOne. 2013 Jul 23;8(7):e69155.

9.       Pan K, Li YQ, Wang W, Xu L, Zhang YJ, Zheng HX, ZhaoJJ, Qiu HJ, Weng DS, Li JJ, Wang QJ, Huang LX, He J, Chen SP, Ke ML, Wu PH,Chen MS, Li SP, Xia JC (Corresponding), Zeng YX. The Efficacy of Cytokine-InducedKiller Cell Infusion as an Adjuvant Therapy for Postoperative HepatocellularCarcinoma Patients. Ann Surg Oncol. 2013 Jul 27.

10.   Huang ZM, Li W, Li S, Gao F, Zhou QM, Wu FM, He N,Pan CC, Xia JC, Wu PH, Zhao M. Cytokine-induced killer cells in combinationwith transcatheter arterial chemoembolization and radiofrequency ablation forhepatocellular carcinoma patients. JImmunother. 2013 Jun;36(5):287-93.

11.   Zhang F, Sun XF, Li YQ, Zhen ZJ, Zheng HX, Zhu J,Wang QJ, Lu SY, He J, Wang J, Pan K, Cai RQ, Chen Y, Weng DS, Sun FF, Xia JC(Corresponding). Safety of in vitro amplified HLA-haploidentical donor immunecell infusions for childhood malignancies. ChinJ Cancer. 2013 May 27. doi: 10.5732 / cjc.012.10298.

12.    Zhao JJ, Pan K,Wang QJ, Xu ZD, Weng DS, Li JJ, Li YQ, Xia JC (Corresponding). Effect ofanti-asthma Chinese medicine Chuankezhi on the anti-tumor activity ofcytokine-induced killer cells. Chin J Cancer. 2013 Mar 8. doi:10.5732/cjc.012.10249.

13.   Huang CY, Chen YM, Zhao JJ,Chen YB, Jiang SS, Yan SM, Zhao BW, Pan K, Wang DD, Lv L, Li YF, Wang W, ZhouZW, Xia JC (Corresponding). Decreased expression of transcription elongationfactor a-like 7 is associated with gastric adenocarcinoma prognosis. PLoS One. 2013;8(1):e54671.

14.   Li JJ, Shan HB, Xu GL, He LJ, Xia JC. Submucosalsaline solution injection combined with endosonography for distinguishingbetween stages T1aand T1b ofearly esophageal cancer. GastrointestEndosc. 2013 Jan;77(1):159-60.

15.   Li JJ, Pan K, Gu MF, Chen MS, Zhao JJ, Wang H, LiangXT, Sun JC, Xia JC (Corresponding). Prognostic value ofsoluble MICA levels in the serum of patients with advanced hepatocellularcarcinoma. Chin J Cancer. 2013Mar;32(3):141-8.

16.   Li YF, Wang DD, Zhao BW, Wang W, Huang CY, Chen YM,Zheng Y, Keshari RP, Xia JC (Corresponding), Zhou ZW. High Level of COP1Expression is Associated with Poor Prognosis in Primary Gastric Cancer. Int J Biol Sci. 2012;8(8):1168-77.

17.   Li YF, Wang DD, Zhao BW, Wang W, Yuan SQ, Huang CY,Chen YM, Zheng Y, Keshari RP, Xia JC (Corresponding), Zhou ZW. Poor prognosisof gastric adenocarcinoma with decreased expression of AHRR. PLoS One. 2012;7(8):e43555.

18.   Wang DD, Chen YY, Pan K, Wang W, Chen SP, Chen JG,ZhaoJJ, Lv L, Pan QZ, Li YQ, Wang QJ, Huang LX, Ke ML, He J, Xia JC(Corresponding). Decreased Expression of the ARID1AGene Is Associated with Poor Prognosis in PrimaryGastric Cancer. PLoS One. 2012; 7(7):e40364

19.    Zhao JJ, Pan K,Wang W, Chen JG, Wu YH, Lv L, Li JJ, Chen YB, Wang DD, Pan QZ, Li XD, Xia JC(Corresponding). The prognostic value of tumor-infiltrating neutrophils ingastric adenocarcinoma after resection. PLoS One. 2012;7(3):e33655.

20.   Li JJ, Gu MF, Pan K, Liu LZ,Zhang H, Shen WX, Xia JC (Corresponding). Autologous Cytokine-InducedKiller Cell Transfusion in Combination with Gemcitabine plus Cisplatin RegimenChemotherapy for Metastatic Nasopharyngeal Carcinoma. J Immunotherapy. 2012 Feb-Mar;35(2):189-95.

21.   Pan K, Liang XT, Zhang HK, Zhao JJ, Wang DD, Li JJ,Lian Q, Chang AE, Li Q, Xia JC (Corresponding).. Characterization of BIN1 as apotential tumor suppressor and prognostic marker in hepatocellular carcinoma. Mol Med. 2012 18:507-18.

22.   Chen Y, Pan K, Li S, Xia J (Corresponding), Wang W,Chen J, Zhao J, Lü L, Wang D, Pan Q, Wang Q, Li Y, He J, Li Q. Decreasedexpression of V-set and immunoglobulin domain containing 1 (VSIG1) isassociated with poor prognosis in primary gastric cancer. J Surg Oncol. 2012 Sep 1;106(3):286-93.

23.   Zhao JJ, Pan K, Li JJ, Chen YB, Chen JG, Lv L, WangDD, Pan QZ, Chen MS, Xia JC (Corresponding). Identification of LZAP as a NewCandidate Tumor Suppressor in Hepatocellular Carcinoma. PLoS One. 2011; 6(10): e26608.

24.   Wang W, Lv L, Pan K, Zhang Y, Zhao JJ, Chen JG, ChenYB, Li YQ, Wang QJ, He J, Chen SP, Xia JC (Corresponding). Reduced expressionof transcription factor AP-2α is associated with gastric adenocarcinomaprognosis. PLoS One. 2011; 6(9):e24897.

25.   Lv L, Pan K, Li XD, She KL, Zhao JJ, Wang W, ChenJG, Chen YB, Yun JP, Xia JC (Corresponding). The accumulation and prognosisvalue of tumor infiltrating IL-17 producing cells in esophageal squamous cellcarcinoma. PLoS One. 2011; 6(3):e18219.

26.   Liang XT, Pan K, Chen MS, Li JJ, Wang H, Zhao JJ,Sun JC, Chen YB, Ma HQ, Wang QJ, Xia JC (Corresponding). Decreased expressionof XPO4 is associated with poor prognosis in hepatocellular carcinoma. J Gastroenterol Hepatol. 2011; 26(3):544-9

27.   Ma H, Liang X, Chen Y, Pan K, Sun J, Wang H, Wang Q,Li Y, Zhao J, Li J, Chen M, Xia J (Corresponding). Decreased expression ofBATF2 is associated with a poor prognosis in hepatocellular carcinoma. Int J Cancer. 2011; 128(4): 771-7.

28.   Chen JG, Xia JC (Corresponding), Liang XT, Pan K,Wang W, Lv L, Zhao JJ, Wang QJ, Li YQ, Chen SP, He J, Huang LX, Ke ML, Chen YB,Ma HQ, Zeng ZW, Zhou ZW, Chang AE, Li Q. Intratumoral Expression of IL-17 andIts Prognostic Role in Gastric Adenocarcinoma Patients. Int J Biol Sci. 2011; 7(1): 53-60.

29.   Ma H, Weng D, Chen Y, Huang W, Pan K, Wang H, Sun J,Wang Q, Zhou Z, Wang H, Xia J (Corresponding). Extensive analysis of D7S486 inprimary gastric cancer supportsTESTIN as a candidate tumor suppressor gene. Mol Cancer. 2010; 9:190.

30.   Pan K, Zhao JJ, Wang H, Li JJ, Liang XT, Sun JC,Chen YB, Ma HQ, Liu Q, Xia JC (Corresponding). Comparative analysis ofcytotoxic T lymphocyte response induced by dendritic cells loaded withhepatocellular carcinoma -derived RNA or cell lysate. Int J Biol Sci. 2010; 6(7): 639-48.

31.   Sun JC, Liang XT, Pan K, Wang H, Zhao JJ, Li JJ, MaHQ, Chen YB, Xia JC (Corresponding). High expression level of EDIL3 inHCC predicts poor prognosis of HCCpatients. World J Gastroenterol. 2010; 16(36): 4611-5.

32.   Wang QJ, Wang H, Pan K, Li YQ, Huang LX, Chen SP, HeJ, Ke ML, Zhao JJ, Li JJ, Sun JC, Liang XT, Ma HQ, Chen YB, Xia JC(Corresponding). Comparative study on anti-tumor immune response of autologouscytokine-induced killer (CIK) cells, dendritic cells-CIK (DC-CIK), andsemi-allogeneic DC-CIK. Chin J Cancer.2010; 29(7): 641-8.

33.   Sun JC, Pan K, Chen MS, Wang QJ, Wang H, Ma HQ, LiYQ, Liang XT, Li JJ, Zhao JJ, Chen YB, Pang XH, Liu WL,Cao Y, Guan XY, Lian QZ, Xia JC(Corresponding). Dendritic cells-mediated CTLs targeting hepatocellularcarcinoma stem cells. Cancer Biol Ther. 2010; 10(4): 368-75.

34.   Ma H, Zhang Y, Wang Q, Li Y, He J, Wang H, Sun J,Pan K, Chen M, Xia J (Corresponding). Therapeutic safety and effects ofadjuvant autologous RetroNectin activated killer cell immunotherapy forpatients with primary hepatocellular carcinoma after radiofrequency ablation. Cancer Biol Ther. 2010; 9(11): 903-7.

35.   Zhang H, Ma H, Wang Q, Chen M, Weng D, Wang H, ZhouJ, Li Y, Sun J, Chen Y, Liang X, Zhao J, Pan K, Wang H, Xia J (Corresponding).Analysis of loss of heterozygosity on chromosome 4q in hepatocellular carcinomausing high-throughput SNP array. OncolRep. 2010; 23(2): 445-55.

36.   Zhou J, Weng D, Zhou F, Pan K, Song H, Wang Q, WangH, Wang H, Li Y, Huang L, Zhang H, Huang W, Xia JC (Corresponding).Patient-derived renal cell carcinoma cells fused with allogeneic dendriticcells elicit anti-tumor activity: in vitro results and clinical responses. Cancer Immunol. Immunother. 2009;58(10): 1587-97.

37.   Pan K, Wang H, Liu W, Zhang H, Zhou J, Li J, Weng D,Huang W, Sun J, Liang X, Xia JC (Corresponding). The pivotal role of p38 andNF-κB signal pathways in the maturation of human monocyte-derived dendriticcells stimulated by streptococcal agent OK-432. Immunobiology 2009; 214(5): 350-358.

38.   Zhang HK, Pan K, Wang H, Weng DS, Song HF, Zhou J,Huang W, Li JJ, Chen MS, Xia JC (Corresponding). Decreased Expression of Ing2Gene and Its Clinicopathological Significance in Hepatocellular Carcinoma. Cancer Lett. 2008; 261(2): 183-192.

39.   Weng DS, Zhou J, Zhou QM, Zhao M, Wang QJ, Huang LX,Li YQ, Chen SP, Wu PH, Xia JC (Corresponding). Minimally Invasive TreatmentCombined with Cytokine-Induced Killer Cells Therapy Lower the Short-TermRecurrence Rates of Hepatocellular Carcinomas. J Immunother. 2008; 31(1): 63-71.

40.   Ma HQ, Liang XT, Zhao JJ, Wang H, Sun JC, Chen YB,Pan K, Xia JC (Corresponding). Decreased expression of Neurensin-2 correlateswith poor prognosis in hepatocellular carcinoma. World J Gastroenterol. 2009; 15(38): 4844-8.

41.   Wang H, Pan K, Zhang HK, Weng DS, Zhou J, Li JJ,Huang W, Song HF, Chen MS, Xia JC (Corresponding). Increased Polycomb-GroupOncogene Bmi-1 Expression Correlates with Poor Prognosis in HepatocellularCarcinoma. J Cancer Res Clin Oncol. 2008; 134(5): 535-541.

42.   Pan K, Wang H, Chen MS, Zhang HK, Weng DS, Zhou J,Huang W, Li JJ, Song HF, Xia JC (Corresponding). Expression and prognosis roleof indoleamine 2,3-dioxygenase in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2008;134(11):1247-1253

43.   Weng DS, Li JT,Mai SJ, Pan ZZ, Feng BJ, Feng QS, Huang LX, Wang QJ,Li YQ, Yu XJ, Chen SP, He J, Xia JC (corresponding). Identification of a newtarget region on the long arm of chromosome7 ingastric carcinoma by loss of heterozygosity. World J Gastroenterol. 2006; 12(15):2437-2440.

44.   Xia JC, Weng DS, Li JT, Qin HD,Mai SJ, Feng BJ, Fan Q, Feng QS,Huang LX, Yu XJ, Pan ZZ, Li YQ, Wang QJ, Zhan YQ, Chen SP, He J, Huang WL, WuPH, Zeng YX. Loss of heterozygosity analysis of a candidate gastric carcinomatumor suppressor locus at 7q31. CancerGenet Cytogenet. 2006; 166(2): 166-172.

45.   Tanaka Y, Koido S, Xia JC (co-firster author), Ohana M, Liu C,Cote GM, Sawyer DB, Calderwood S, Gong J. Development of Antigen-Specific CD8+Cytotoxic T Lymphocytes in MHC Class I-Deficient Mice through CD4 to CD8Conversion. J Immunol. 2004; 172:7848-7858.

46.   Xia JC, Tanaka Y, Koido S, Liu C, Mukherjee P,Gendler SJ, Gong J. Prevention of spontaneous breast carcinoma by prophylacticvaccination with dendritic/tumor fusion cells. J Immunol. 2003; 170 (4): 1980-1986.

Patient care improvement
Zhang Li's Laboratory

Zhang Li’s laboratory is part of The State Key Laboratory (SKL) of Oncology in South China, Sun Yat-sen University Cancer Center. The Zhang lab focuses on developing molecular, prognostic and therapeutic approaches to improve the care for patients with lung cancer, colorectal cancer and nasopharyngeal carcinoma.

Current Research
Clinical research of newly developed anti-cancer drugs
Genetic and molecular classification research of lung cancer and nasopharyngeal carcinoma
Mechanism research of anti-cancer targeted drugs
Palliative care for terminal cancer patients

Contact Information
Li Zhang
Principle Investigator
Professor of Medical Oncology
Director of Clinical Study Center
Director of Phase I Unite
Sun Yat-Sun University Cancer Center

651 Dong Feng Road, East Guangzhou,China 510060

Translation of novel genetic biomarkers of various malignancies into clinical practice
Shao Jian-Yong's Laboratory

Personalized Medicine is quickly becoming a mainstay in the medical development. However, Personalized Medicine in Oncology is still at a nearly stage. To improve the prevention, diagnosis and treatment of tumor, we devote ourselves to the translation of novel genetic biomarkers of various malignancies into clinical practice. Our laboratory also maintains a specific interest in clinical and basic research about pathogenesis, molecular genotyping and personalized treatment of nasopharyngeal carcinoma. We developed a eight-signature classifier for prediction of nasopharyngeal carcinoma prognosis from a series of candidate biomarkers by SVM algorithm, including sex and seven genes, Epstein-Barr virus latency membrane protein 1, CD147, caveolin-1, phospho-P70S6 kinase, MMP11, survivin,and SPARC (Journal of Clinical Oncology 2011, 29: 4516-1525). And we identified profiling plasma microRNA in nasopharyngeal carcinoma with deep sequencing and quantitative realtime-PCR (Clinical Chemistry 2014, 60: 773-782). The study of miRNAs in breast cancer led to discovery of up-regulated miR-21 and down-regulated miR-125b in breast cancer that correlated well with patient’s prognosis and metastasis, which in turn has served as the basis for the development of targeted therapy for breast cancer(RNA. 2008 14: 2348-2360.; Cancer Res.,2011, Breast Cancer Research,2011; Breast Cancer Research 2011;13(1):R2; Cancer Res. 2011;71(10):3552-62).  Through collaborative research studies combining basic, translational, and clinical approaches we are seeking to understand triggers of nasopharyngeal carcinoma progression and develop better tools to monitor responses to targeted therapy of various cancers especially for nasopharyngeal carcinoma, lung cancer, breast cancer, stomach cancer and colorectal cancer. Our research group started researching for miRNA in cancers in the early stage, and our studies are widely accepted and have high international influence.

Contact Information
Administrative Offices

Department of Molecular Diagnostics, Sun Yat-sen University Cancer Center, 21 Qing Cai Gang Road, Guangzhou, 510060, People’s Republic of China;
Tel: +86 020 8734 5599;
Fax: +86-020-87345599;
Email : 

Lab Members

Current Lab Members

Shao Jian-yong,MD., PhD., Principal Investigator

-  He Cai-Yun, PhD., Research Assistant

-  Cen Wen-Jian, technician

-  Ph.D and postgraduate students: Wang Fang, Fu Sha, Zhu Hao-Tu, Xu Cui-Wei, Xie Guo-Feng, Liu Rong-bin, FengYan-Fen, Abdulbaqi, and Wang Jing  



YaoKai-Tai, MD., PhD., Southern Medical University

Cao Ya, MD.,PhD., Xiangya Medical College of South Central University

Gao Li andZhang Zhi-Hui, MD., PhD., Cancer Hospital, Chinese Academy of Medical Sciences

ZhengYu-Min, MD., PhD., Wuzhou Red Cross Hospital

Labs and Equipment

ShaoJian-Yong Laboratory is located in the Department of Molecular diagnostics at Sun Yat-sen University Cancer Center (SYSUCC). It is an outstanding environment for basic science and translational research. There is a strong core of PhD, graduate and undergraduate students that contribute to the research. Prof. Shao Jian-Yong serves as the leader of our research group, who successively presides over or is mainly responsible for two projects of National Major Fundamental Research Program of China (973 and 863 programs) and 16 projects of Natural Science Foundation of China or Science Project of Guangdong Province, in addition to which he joins in 15 other research projects in China. The research in the Department is also greatly enhanced by SYSUCC.

GMP Certified Workshops


GMP (Good Manufacturing Practice) certified workshops are separately used for reagent preparation, nuclear acid extraction, PCR amplification and PCR product electrophoresis.

Specialized Labs


We set up several specialized labs for nucleic acid amplification, Sanger sequencing, Next-Generation sequencing, genotyping, FISH(fluorescence in situ hybridization), and molecular biology.

 Sequencing and Microarray Facility

The Sequencing and Microarray Facility provides our research group with reliable nucleic acid analysis. There are internationally advanced gene-testing systems including Cobas z480 and ABI7500 realtime-PCR amplifier, ABI3500XL genetic analyzer, W2600SPR biosense chip analyzer, Sequenom MassARRAY platforms,and Next-Generation sequencing system. The goal of our laboratory is to establish an advanced international testing center that adapt to high-throughput, moderate-throughput or low-throughput test for genetics and genomics research.

Microscopy Facility

The laboratory maintains a modern Microscopy Core with multiple platforms for live imaging, fluorescent imaging, bright field microscopy, etc. Imaging is supported by numerous software programs for processing and analyzing data sets.

Molecular Biological Facility

The primary goal of these molecular biological facilities is to offer conventional and molecular cytogenetic services for genotyping, analysis of gene expression,cell culture and so on.


Research Interests

The post-genomic era has provided unprecedented opportunity to examine the complex role of aberrant gene expression and regulation in the development and progression of cancer. The goal of our work is to develop molecular classification and molecular target for cancers by using various molecular biological methods. We believe that a clearer understanding of these biomarkers will translate into advancements in personalized diagnosis and treatment of cancer.

Chromosome 7 Disomy Predicts Resistance to Cetuximab inKRAS Wild-type Metastatic Colorectal Cancer Patients

Li,Y.H., et al., Clin Cancer Res, 2011.17(2): p. 382-90.PMID: 20884623

FISH detection of EGFR copy and chromosome 7 disomy.A,EGFR gene focal amplification in tumor cells. B, increase in EGFR gene copy number and polysomy of chromosome 7. C, homogenous of EGFR gene copy number with a homogeneous chromosome 7 Trisomy. D, no EGFR gene copy number and chromosome 7 disomy alteration pattern.

Metastatic colorectal cancer patients with low epidermal growth factor receptor (EGFR)gene copy number are unlikely to respond to anti-EGFR monoclonal antibody (mAb)treatment. Our results showed firstly that it may be feasible to consider EGFR FISH pattern of chromosome 7 disomy as a negative predictive factor for cetuximab response in KRAS wild-type metastatic colorectal cancer. Together with KRAS mutation, chromosome 7 disomy predicts metastatic colorectal cancer patients will not respond to cetuximab.

Eight-Signature Classifier for Prediction of Nasopharyngeal Carcinoma Survival

Wang, H.Y., et al., J Clin Oncol, 2011.29(34): p. 4516-25.

Receiver operating characteristic (ROC) curves and Kaplan-Meier survival estimates of evaluated patients with nasopharnyngeal carcinoma (NPC) from both training and validation cohorts. ROC curves for molecular markers, age at diagnosis, WHO histologic classification, sex, clinical stage, and NPC–support vector machine (SVM) classifier as predictors of death as result of NPC within 5 years in (A) training and (B) validation cohorts. Kaplan-Meier survival estimates for low- and high-risk patients with NPC as defined by NPC-SVM classifier. Disease-specific survival curves of evaluated patients in (C) training and (D) validation cohorts.

Currently, nasopharyngeal carcinoma (NPC) prognosis evaluation is based primarily on the TNM staging system. We used support vector machine (SVM) –based methods to develop a prognostic classifier for NPC (NPC-SVM classifier) from 18 biomarkers. The NPC-SVM classifier integrated patient sex and the protein expression level of seven genes, including Epstein-Barr virus latency membrane protein 1, CD147, caveolin-1, phospho-P70S6 kinase, matrix metalloproteinase 11, survivin, and secreted protein acidic and rich in cysteine. This classifier distinguished patients with NPC into low- and high-risk groups with significant differences in 5-year DSS in the evaluated patients and in the validation cohort. The newly developed NPC-SVM classifier based on tumor-associated biomarkers will facilitate patient counseling and individualize management of patients with NPC.

miR-125bis Methylated and Functions as a Tumor Suppressor by Regulating the ETS1 Proto-oncogene in Human Invasive Breast Cancer

Zhang, Y.,et al., Cancer Res, 2011.71(10): p. 3552-62.

ETS1 is a direct target of miR-125b and knockdown of ETS1 suppresses cell growth, proliferation, and induces G1 cell-cycle arrest.

The miR-125b is dysregulated in various human cancers but its underlying mechanisms of action are poorly understood. We report that miR-125b is down regulated in invasive breast cancers where it predicts poor patient survival. Hypermethylation of the miR-125b promoter partially accounted for reduction of miR-125b expression in human breast cancer. Ectopic restoration of miR-125b expression in breast cancer cells suppressed proliferation, induced G1 cell-cycle arrest in vitro, and inhibited tumorigenesis in vivo. We identified the ETS1 gene as a novel direct target of miR-125b. siRNA-mediated ETS1 knockdown phenocopied the effect of miR-125b in breast cell lines and ETS1 overexpression in invasive breast cancer tissues also correlated with poor patient prognosis. Our findings point to an important role for miR-125b in the molecular etiology of invasive breast cancer, and they suggest miR-125b as a potential theranostic tool in this disease.

Active Research Projects

Funding Sources

Project Name

Project Number

863 project

Molecular Genotyping and Personalized Diagnosis and Treatment of Major Diseases


973 project

Molecular Mechanism of Viral Latent Infection



Molecular Genotyping and Personalized Diagnosis and Treatment of Major Diseases


the National Science Foundation

Study on the Mechanism of miR-30 in Regulation Invasion and Metastasis of Nasopharyngeal Carcinoma


the National Science Foundation

The Molecular Mechanism and Clinical Significance of miR-29a regulating the Epithelial Mesenchymal Transition in Nasopharyngeal Carcinoma


 Lectures and Seminars

Academic reports made by Prof. Shao Jian-Yong at important domestic and international conferences in 2013




NPC Histological  Diagnosis for NIH GrantRo1






















第九届中国病理主任会与Journal of pathology联合会议暨分子病理与病理学术研讨会


Research forums in primary medical units


Country-level continuing education projects for the Application of Molecular Pathology Techniques in Oncology Treatment


 News & Awards



Second Prize of the State Natural Science Award and First Reward of the Science and Technology Progress in Guangdong Province



1.    Wang HY, Yan LX, Shao Q, Fu S, Zhang ZC, Ye W, Zeng YX, Shao JY*.Profiling Plasma MicroRNA in Nasopharyngeal Carcinoma with Deep Sequencing.Clin Chem. 2014 60: 773-782 (IF=7.149)

2.    Fu S,Wang F,Shao Q,Zhang X,Duan LP,Zhang X,Zhang L,Shao JY*.Detection of EML4-ALK FusionGene in Chinese Non-Small Cell Lung Cancer by Using a Sensitive QuantitativeReal-Time Reverse Transcriptase PCR Techniqu.Diagn Mol Pathol.2014 Jan 30.(IF=1.861)

3.    Zhang ZC,Li YY,Wang HY,Fu S,Wang XP,Zeng MS,Zeng YX,Shao JY*.Knockdown of miR-214Promotes Apoptosis and Inhibits Cell Proliferation in Nasopharyngeal Carcinoma.PLoS One.2014 21;9(1):e86149.(IF=3.73)

4.    Jia SW,Fu S,Wang F,Shao Q,Huang HB,Shao JY*. ALK gene copy number gainand its clinical significance in hepatocellular carcinoma.World JGastroenterol.2014 Jan 7;20(1):183-92. (IF=2.547)

5.     Zhao ZR. Wang JF. Lin YB. WangF. Fu S. Zhang SL. Su XD. Jiang L. Zhang YG.Shao JY*. Long H..Mutation abundance affects the efficacy of EGFRtyrosine kinase inhibitor readministration in non-small-cell lung cancer withacquired resistance. Med Oncol.2014 Jan;31(1):810. (IF=2.147)

6.    Li YY,Fu S,Wang XP,Wang HY,Zeng MS,Shao JY*. Down-regulation of c9orf86in human breast cancer cells inhibits cell proliferation, invasion and tumorgrowth and correlates with survival of breast cancer patients.PLoS One.2013 Aug 14;8(8):e71764.(IF=3.73)

7.    WangF, FuSShaoQ, Zhou YB,ZhangX,ZhangX,XueC,LinJG,HuangLX, ZhangL,ZhangWM, and ShaoJY*. High EGFR copy numberpredicts benefits from tyrosine kinase inhibitor treatment for non-small celllung cancer patients with wild-type EGFR. J Transl Med. 2013; 11: 90.(IF= 3.459)

8.    Zhang JXCai MBWang XPDuan LPShao QTong ZTLiao DZLi YYHuang MY,Zeng YXShao JY*.Elevated DLL4expression is correlated with VEGF and predicts poor prognosis ofnasopharyngeal carcinoma.Med Oncol. 2013 Mar;30(1):390. (IF= 2.147)

9.    Hu CWei WChen XWoodman CBYao YNicholls JMJoab ISihota SKShao JY,Derkaoui KDAmari AMaloney SLBell AIMurray PGDawson CWYoung LS,Arrand JR.A global view ofthe oncogenic landscape in nasopharyngeal carcinoma: an integrated analysis atthe genetic and expression levels.PLoS One. 2012;7(7):e41055. (IF=3.73)

10. Cai MBHan HQBei JXLiu CCLei JJCui QFeng QSWang HYZhang JXLiang YChen LZKang TBShao JYZeng YX.Expression ofhuman leukocyte antigen G is associated with prognosis in nasopharyngealcarcinoma.Int J Biol Sci. 2012;8(6):891-900. (IF= 3.168)

11. Li XJPeng LXShao JYLu WHZhang JXChen SChen ZYXiang YQBao YN,Zheng FJZeng MSKang TBZeng YXTeh BTQian CN.As anindependent unfavorable prognostic factor, IL-8 promotes metastasis ofnasopharyngeal carcinoma through induction of epithelial-mesenchymal transitionand activation of AKT signaling.Carcinogenesis. 2012 Jul;33(7):1302-9.(IF= 5.635)

12. Cai MBWang XPZhang JXHan HQLiu CCBei JXPeng RJLiang YFeng QS,Wang HYChen LZFu SKang TShao JYZeng YX.Expression ofheat shock protein 70 in nasopharyngeal carcinomas: different expressionpatterns correlate with distinct clinical prognosis.J Transl Med. 2012 May 16;10:96. (IF=3.459)

13. Wang HY, Li YY, Shao Q, Hou JH, Wang F, Cai MB, Zeng YX, Shao JY*.Secreted protein acidic and rich in cysteine (SPARC) is associated withnasopharyngeal carcinoma metastasis and poor prognosis.J Transl Med.2012;10(1):27.(IF= 3.459)

14.  Du ZM,Kou CW, Hu CF, Chen J, Wang HY, Yan LX, Ernberg I, Zeng YX, and Shao JY*.Clinical Significance of Elevated Spleen Tyrosine Kinase Expression inNasopharyngeal Carcinoma. Head and Neck,2012.doi: 10.1002/hed.21953. (IF= 2.833)

15.  ZhangLJ, Cai L, Li Z, Wang WP, Guo K, Shao JY, Wang JY, Yu H, Rong TH. Relationshipbetween epidermal growth factor receptor gene mutation and copy number inChinese patients with non-small cell lung cancer. Chin J Cancer. 2012. Hai-YunWang, Bing-Yu Sun, Zhi-Hua Zhu, Ellen T. Chang, Ka-Fai To, Jacqueline S.G.Hwang, Hao Jiang,Michael Koon-Ming Kam, Gang Chen, Shie-Lee Cheah, Ming Lee,Zhi-Wei Liu, Jing Chen, Jia-Xing Zhang,Hui-Zhong Zhang, Jie-Hua He, Fa-LongChen, Xiao-Dong Zhu, Ma-Yan Huang, Ding-Zhun Liao, Jia Fu,Qiong Shao, Man-BoCai, Zi-Ming Du, Li-Xu Yan, Chun-Fang Hu, Ho-Keung Ng, Joseph T.S. Wee,Chao-NanQian, Qing Liu, Ingemar Ernberg, Weimin Ye, Hans-Olov Adami, Anthony T. Chan,Yi-Xin Zeng,and Shao JY*. An Eight-signature Classifier for Prediction ofNasopharnyngeal Carcinoma Survival. Journal of Clinical Oncology, 2011; 29(34):4516-4525. (IF=18.083)

16.  Du ZM,Hu LF, Wang HY, Yan LX, Zeng YX, Shao JY*, Ernberg I. Upregulation of MiR-155in Nasopharyngeal Carcinoma is Partly Driven by LMP1 and LMP2A andDownregulates a Negative Prognostic Marker JMJD1A. PLoS One. 2011; 6(4):e19137.(IF= 3.73)

17.  ZhangY, Yan LX, Wu QN, Du ZM, Chen J, Liao DZ, Huang MY, Hou JH, Wu QL, Zeng MS,Huang W, Zeng YX, Shao JY*. miR-125b is Methylated and Functions as A TumorSuppressor by Regulating the ETS1 proto-oncogene in Human Invasive BreastCancer. Cancer Res. 2011;71(10):3552-62. (IF= 8.65)

18.  Li XJ,Ong CK, Cao Y, Xiang YQ, Shao JY, Ooi A, Peng LX, Lu WQ, Zhang ZF, Petillo D,Lin Q, Bao YN, Zheng FJ, Claramae SC, N Gopalakrishna lyer, Kang BT, Zeng YX,Khee CS, Jeffrey MT, Teh BT, Qian CN. Serglycin Is a Theranostic Target inNasopharyngeal Carcinoma that Promotes Metastasis. Cancer Res.2011;71(8):3162-3172. (IF= 8.65)

19.  An X,Wang FH, Ding PR, Deng L, Jiang WQ, Zhang L, Shao JY, Li YH. Plasma Epstein-Barrvirus DNA level strongly predicts survival in metastatic/recurrentnasopharyngeal carcinoma treated with palliative chemotherapy. Cancer 2011;117(16):    3750-7. (IF= 5.201)

20.  YanLX, Wu QN, Zhang Y, Li YY, Liao DZ, Hou JH, Fu J, Zeng MS, Yun JP, Wu QL, ZengYX, Shao JY*. Knockdown of miR-21 in human breast cancer cell lines inhibitsproliferation, in vitro migration and in vivo tumor growth. Breast Cancer Res.2011;13(1):R2. (IF= 5.872)

21. Li YH, Wang F, Shen L, Deng YM, Shao Q,Feng F, An X, Wang FH, Wang ZQ, Xu RH, Shao JY*. EGFR FISH Pattern ofChromosome 7 Disomy Predicts Resistance to Cetuximab in KRAS Wild-typeMetastatic Colorectal Cancer Patients. Clin. Cancer Res. 2011;17(2):382-90.(IF= 7.837)

22.  ShaoJY*, Cao Y, Miao XP, Huang MY, Deng L, Hao JJ, Liang XM, Hu LF, Ingemar E, LinDX, Zeng YX. A single nucleotide polymorphism in the Matrix Metalloproteinase-2promoter is closely associated with high risk of nasopharyngeal carcinoma inCantonese from southern China. Chin. J. Cancer, 2011;30(9):620-6. (IF= 0.448)

23.  Cao Y,Miao XP, Zeng YX, Lin DX, Shao JY*. Association between genetic polymorphismsof CYP2A13, CYP2A6 and risk of nasopharyngeal carcinoma in southern Chinesepopulation. Cancer Biology, 2011;1(1). (IF= 3.287)

24.  ZhangY, Hu CF, Chen J, Yan LX, Zeng YX, Shao JY*. LATS2 is de-methylated andoverexpressed in nasopharyngeal carcinoma and predicts poor prognosis. BMCCancer. 2010;10:538. (IF= 3.333)

25. Cao Y, Miao XP, Huang MY, Deng L, Lin DX, Zeng YX, Shao JY*. Polymorphisms of death pathway genes FAS and FASL and risk of nasopharyngeal carcinoma. Mol. Carcinog. 2010;49(11):944-50. (IF= 4.269)

26. Cao Y, Miao XP, Huang MY, Deng L, LiangXM, Lin DX, Zeng YX, Shao JY*. Polymorphisms of methylenetetrahydrofolatereductase are associated with a high risk of nasopharyngeal carcinoma in asmoking population from southern China. Mol. Carcinog. 2010;49(11):928-34. (IF=4.269)

27. Kong QL, Hu LJ, Cao JY, Huang YJ, XuLH, Liang Y, Xiong D, Guan S, Guo BH, Mai HQ, Chen QY, Zhang X, Li MZ, Shao JY,Qian CN, Xia YF, Song LB, Zeng YX, Zeng MS.Epstein-Barr virus-encoded LMP2Ainduces an epithelial-mesenchymal transition and increases the number of sidepopulation stem-like cancer cells in nasopharyngeal carcinoma. PLoS Pathog.2010; 6(6):e1000940. (IF= 8.136)

28. Valentine R,Dawson CW,Hu C,Shah KM,Owen TJ,Date KL,Maia SP,Shao J,Arrand JR,Young LS,O'Neil JD.Epstein-Barr virus-encoded EBNA1 inhibits the canonical NF-kappaB pathway incarcinoma cells by inhibiting IKK phosphorylation.Mol Cancer.2010;9:1. (IF= 5.134)

29.  Guo BH, Zhang X, Zhang HZ, LinHL, Feng Y, Shao JY, Huang WL, Kung HF, Zeng MS. Low expression of Mel-18predicts poor prognosis in patients with breast cancer. Ann Oncol.2010;21(12):2361-9. (IF= 7.384)

30.  Chen J, Hu CF, Hou JH, Shao Q,Yan LX, Zhu XF, Zeng YX and Shao JY*. Epstein-Barr Virus Encoded LatentMembrane Protein 1 Regulates mTOR Signaling Pathway Genes Which Predict PoorPrognosis of Nasopharyngeal Carcinoma. J. Transl. Med. 2010;8:30. (IF= 3.459)

31. Du ZM,Hu CF,Shao Q,Huang MY,Kou CW,Zhu XF,Zeng YX,Shao JY*.Upregulation ofcaveolin-1 and CD147 expression in nasopharyngeal carcinoma enhanced tumor cellmigration and correlated with poor prognosis of the patients.Int. J. Cancer.2009; 125(8):1832-41. (IF=6.198)

32.  Yan LX, Huang XF, Shao Q,Huang MY, Deng L, Wu QL, Zeng YX, Shao JY*. MicroRNA miR-21 Overexpression inHuman Breast Cancer is Associated with Advanced Clinical Stage, Lymph NodeMetastasis and Patient Poor Prognosis. RNA. 2008 14: 2348-2360. (IF= 5.088)

33.  Pang LJ, Shao JY*, Liang XM,Xia YF, Zeng YX. Mitochondrial DNA somatic mutations are frequent innasopharyngeal carcinoma. Cancer Biol. Ther. 2008, 7(2):198-207. (IF= 3.287)

34.  Li YH, Hu CF, Shao Q, HuangMY, Hou JH, Xie D, Zeng YX, Shao JY*. Elevated Expressions of Survivin and VEGFProtein Are Strong Independent Predictors of Survival in AdvancedNasopharyngeal Carcinoma. J Transl Med. 2008, 3;6(1):1. (IF= 3.459)

35. Zhu ZH,Sun BY,Ma Y,Shao JY,Long H,Zhang X,Fu JH,Zhang LJ,Su XD,Wu QL,Ling P,Chen M,Xie ZM,Hu Y,Rong TH.Threeimmunomarker support vector machines-based prognostic classifiers for stage IBnon-small-cell lung cancer.J Clin Oncol.2009; 27(7): 1091-9. (IF=18.038)

36. Cheung AK,Lung HL,Hung SC,Law EW,Cheng Y,Yau WL,Bangarusamy DK,Miller LD,Liu ET,Shao JY,Kou CW,Chua D,Zabarovsky ER,Tsao SW,Stanbridge EJ,Lung ML.Functional analysisof a cell cycle-associated, tumor-suppressive gene, protein tyrosinephosphatase receptor type G, in nasopharyngeal carcinoma.Cancer Res.2008;68(19):8137-45. (IF=8.65)

37.  Cao Y, Miao XP, Huang MY, DengL, Hu LF, Ernberg I, Zeng YX, Lin DX, Shao JY*. Polymorphisms of XRCC1 genesand risk of nasopharyngeal carcinoma in the Cantonese population. BMC Cancer,2006, 6:167. (IF= 3.333)

38. Li Y, Shao JY, Liu RY, Zhou L, Chai LP, Li HL, HanHY, Huang BJ, Zeng MS, Zhu XF, Liu Q, Fu LW, Huang WEvaluation of Long-TermToxicity of Ad/hIFN-gamma, an Adenoviral Vector Encoding the HumanInterferon-gamma Gene, in Nonhuman Primates.Hum Gene Ther.2008;19(8):827-39. (IF=4.019)

39.  Liu MZ, Xie D, Mai SJ, TongZT, Shao JY, Fu YS, Xia WJ, Kung HF, Guan XY, Zeng YX. Overexpression of AIB1in nasopharyngeal carcinomas correlates closely with advanced tumor stage.Am J Clin Pathol.2008;129(5):728-34. (IF=2.881)

40.  Li HL , Li S , Shao JY , LinXB , Cao Y , Jiang WQ , Liu RY , Zhao P , Zhu XF , Zeng MS , Guan ZZ , Huang W.Pharmacokinetic and pharmacodynamic study of intratumoral injection of anadenovirus encoding endostatin in patients with advanced tumors.Gene Ther.2008;15(4):247-56. (IF=4.321)

41.  Song LB; Zeng MS; Liao WT,Zhang Ling, Mo HY, Liu WL, Shao JY, Wu QL, Li MZ, Xia YF, Fu LW, HuangWL,Goberdhan PD, Vimia B, Zeng YX. Bmi-1 is a novel molecular marker ofnasopharyngeal carcinoma progression and immortalizes primary humannasopharyngeal epithelial cells. Cancer Res. 2006;6(12):6225-32. (IF= 8.65)

42. Pan ZG, Kashuba VI, Liu XQ, Shao JY, Zhang RH, JiangJH, Guo C, Eugene Z, Ingemar E, Zeng YX.Highfrequency somatic mutations in RASSF1A in nasopharyngeal carcinoma. CancerBiol Ther. 2005;4(10):1116-22. (IF= 3.287)

43.  Pan ZZ, Wan DS, Zhang CQ, ShaoJY, Li LR, Chen G, Zhou ZW, Wang FL. Using p53-immunostained large specimens todetermine the distal intramural spread margin of rectal cancer. World JGastroenterology,2006;12(10):1626-9.(IF= 2.547)

44.  Shao JY,Li YH, Zhang Y, et al. Comparison of Plasma Epstein-Barr Viruses DNA Level and Serum EBV VCA/IgAAntibody Titers in Nasopharyngeal Carcinoma. Cancer, 2004, 100: 1162-1170. (IF=5.201)

45.  Shao JY, Ernberg I, Biberfeld,et al. Immunostaining studies on nasopharyngeal carcinoma: Interaction of tumorcells, lymphocytes and expression of EBV LMP1. Anticancer Research, 2004,24(4):2309-2318. (IF= 1.872)

46. Shao JY,Gao HY,Li YH,Zhang Y,Lu YY,Zeng YX. Quantitative detection ofcommon deletion of mitochondrial DNA in hepatocellular carcinoma andhepatocellular nodular hyperplasia.World JGastroenterol.2004;10(11):1560-4. (IF= 2.547)

47.  Shao JY, Gao HY, Li YH, et al.High frequency of common deletion (4981 bp) in mitochondrial DNA innasopharyngeal carcinoma and its correlation with patient age and clinicalstages. Cancer Biology & Therapy, 2004, 3(12):1270-1274. (IF= 3.287)

48.  Shao JY,Zhang Y, Li YH, et al. Comparison of Epstein-Barr virus DNA level in plasma, peripheral bloodcell and tumor tissue in nasopharyngeal carcinoma: correlations with clinicalparameters.  Anticancer Research,2004,24(6):4059-4066. (IF= 1.713)

49.  Shao JY,Li YH, Wu QL, et al. High frequency loss of heterozygosity on the long arm of chromosome 13 and14 in nasopharyngeal carcinoma in Southern China. Chinese Medical Journal,2002, 115(4):571-575. (IF=0.901)

50.  Shao JY,Huang XM, Yu XJ, et al. Loss of Heterozygosity and its correlation with clinical outcome andEpstein-Barr Virus Infection in Nasopharyngeal Carcinoma. Anticancer Research,2001, 21(4): 3021-3030. (IF= 1.713)

51.  Shao JY,Wang HY, Huang XM, et al. Genome-wide allelotype analysis of sporadic primary nasopharyngealcarcinoma from southern China. Int. J Oncology, 2000, 17: 1267-1275. (IF=2.657)

52.  Xiaoming H, Haiqiang M,Manquan D, Jianyong S, Yong S, Kela L, Xiaoman L, Tengbo H. Examinationof nasopharyngeal epithelium with contact endoscopy. Acta Otolaryngol,2001: 121: 95-102. (IF= 1.106)

53.  Guo X, Min HQ, Zeng MS, QianCN, Huang XM, Shao JY, Hou JH. nm23-H1 expression innasopharyngeal carcinoma: correlation with clinical outcomes. Int. J.Cancer, 79(6):596-600, 1998. (IF= 5.007)

Influences of tumor microenvironments on infiltrating immune cells
Limin Zheng's Laboratory

Tumor progression is now recognized as the product of evolving cross talk between different cell types within the tumor and its stroma. Normal stroma is non-permissive for neoplastic progression, but cancer cells can modulate adjacent stroma to generate a supportive microenvironment. With the combination of clinical sample examination and the in vitro/in vivo study, Zheng’s Lab systematically investigate the influences of tumor microenvironments on infiltrating immune cells and how these"educated" cells promote tumor progression.

Current Projects
Tumor-associated myeloid cells
Treg cells, Th17 cell and tumors

Contact Information
Limin Zheng
Professor and Director for Biotherapy Department
Sun Yat-sen University Cancer Center
Vice Dean at School of Life Sciences
Sun Yat-sen University
Tel: +86-20-84112163

Identify and Map the Susceptibility Genes Contributing to NPC
Zeng Yixin's Laboratory

The pathogenesis of nasopharyngeal carcinoma (NPC) is highly related to genetic, Epstein-Barr Virus (EBV) infection and environmental risk factors. Under the supervision of Dr. Zeng, our lab aims to identify and map the susceptibility genes contributing to the NPC through next generation sequencing technology. We also lay an emphasis on elucidating the underlying molecular mechanism between those susceptibility genes and tumorigenesis. On the other hand, we are trying to find out if there will be NPC-associated EBV subtypes of high pathogenecity, as EBV infection is a well-known risk factor and commonly observed in NPC. Our lab employs multidisciplinary approaches and techniques, including genome wide association study (GWAS), cell culture system, molecular biology study and bioinformatics analysis.

Current Research
1. Identification and functional characterization of nasopharyngeal (NPC) susceptibility genes

2. Identification and functional characterization of NPC associated Epstein-Barr Virus (EBV) subtypes

3. Gene, EBV and environment interactions in the pathogenesis of NPC

4. Cancer biotherapy and intervene of EBV in the early stage of NPC pathogenesis

Contact information
Yi-Xin Zeng, M.D., Ph.D.
Department of Laboratory Research
Sun Yat-sen University Cancer Center

651 Dongfeng Road East,
Guangzhou, 510060
Guangdong Province, China

Research on anticancer drugs
Fu Liwu's Laboratory

The laboratory of Fu Liwu, within the State Key Laboratory of Oncology in South China, SYSUCC. Fu's Lab is interested in: 1) Research and development of new anticancer drug; 2) Cancer drug susceptibility testing system, realizing individualized chemotherapy; 3) Research on multiple drug resistance (MDR) mechanism and development of reversal agent for it.

Current Research
1. Pre-clinical research and development of PBA2

2. Development of new anticancer drugs based on abnormal tumor metabolism

3. Dynamic evolution of and intervention study on cancer stem cells

4. Research and development of key technology for large-scale continuous perfusion culture of animal cells

5. Research and development of molecular basis of drug resistance in lung cancer cell and lung cancer drug susceptibility chip for it

6. Research on Afatinib inhibiting expression and functions of ABCG2, thus enhancing effects of anticancer drugs targeting and killing cancer stem cells

7. FG020326 and its homolog reverse ABC-mediated MDR

8. Effect and mechanism of missing or mutation of MED12 in drug resistance in EGFR-TKIs

9. Research on molecular mechanism of acquired drug-resistance in EGFR-TKIs for ErbB4-pathway-mediated non-small cell lung cancer

Contact Information
Prof. Fu Liwu, PhD
Professor and Director of the Experimental Research Department
Sun Yat-sen University Cancer Center

651 Dongfeng East Road
Guangzhou,Guangdong 510060

Signal transduction and targeted drugs in cancer, cancer stem cells and autophagy in nasopharyngeal carcinoma and ovarian cancer
Zhu Xiao-feng's Laboratory

The laboratory of Xiao-Feng Zhu, Ph.D. is within the State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center. The research interests of Zhu Lab include signal transduction and targeted drugs in cancer, cancer stem cells and autophagy in nasopharyngeal carcinoma and ovarian cancer.  

Current Research
1. The role of Beclin 1 modification in anticancer drug-mediated autophagy 
2. Autophagic degradation in cancer
3. Akt regulating autophagy and apoptosis and small molecules targeting akt pathway
4. Molecular targets identification in cancer stem cells
5. The mechanism of drug resistance to chemotherapeutics in ovarian cancer

Contact Information
Xiao-Feng Zhu, Ph.D.
Principle Investigator,
State Key Laboratory of Oncology in South China
Collaborative Innovation Center for Cancer Medicine
Sun Yat-Sen University Cancer Center

Room 805, the 2th Building,
No.651 Dongfeng Road East,
Guangzhou 510060, China.
Office: +86-20-87343149
Fax: +8620-87343170

Where are we | Contact us|

Copyright:Sun Yat-sen University Cancer Center Designed by Wanhu.